/
ORGO
$2.42-$0.01 (-0.41%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$312.7M
129M shares
52-week range
$2.04 – $7.08
8% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.55%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-14.20
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $193.4M | $261.0M | $338.3M | $467.4M | $450.9M | $433.1M | $482.0M | $563.0M |
| Cost of revenue | $68.8M | $75.9M | $87.3M | $114.2M | $105.0M | $106.5M | $115.7M | $137.5M |
| Gross profit | $124.6M | $185.0M | $251.0M | $353.2M | $345.9M | $326.7M | $366.3M | $425.5M |
| Gross margin | 64.4% | 70.9% | 74.2% | 75.6% | 76.7% | 75.4% | 76.0% | 75.6% |
| R&D | $10.7M | $14.8M | $20.1M | $30.7M | $39.8M | $44.4M | $50.3M | $44.5M |
| Operating income | −$51.6M | −$29.9M | $26.7M | $72.2M | $22.3M | $12.5M | −$1.3M | $55.9M |
| EBITDA | −$46.9M | −$19.7M | $37.2M | $87.0M | $40.3M | $36.0M | $15.8M | $73.9M |
| Net income | −$64.8M | −$38.7M | $17.2M | $94.2M | $15.5M | $4.9M | $861.0K | $37.0M |
| Net margin | -33.5% | -14.8% | 5.1% | 20.2% | 3.4% | 1.1% | 0.2% | 6.6% |
| EPS (diluted) | -0.94 | -0.44 | 0.15 | 0.70 | 0.12 | 0.04 | -0.01 | 0.15 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $283M | $-0.82 | $-0.83–$-0.81 | 1 |
| 2027 | $340M | $-0.27 | $-0.32–$-0.23 | 2 |
| 2028 | $372M | $-0.14 | $-0.17–$-0.11 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.45
Price
$2.42
Implied upside
+1%
Peer comparison
Organogenesis Holdings Inc. Class A Common Stock
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
www.organogenesis.com- Employees
- 854
- IPO / List date
- Nov 29, 2016
- HQ
- CANTON, MA
Held by traders on TradeandTell
No one on the platform currently holds ORGO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,068,538 | $2.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ORGO yet.
